Pixium Vision S.A. (PXMVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pixium Vision S.A. (PXMVF) trades at $1.50 with AI Score 43/100 (Grade C). Pixium Vision S. A. Market cap: $4.62M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for PXMVF: PXMVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PXMVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PXMVF: the 1 perspectives are evenly split.
How is this calculated? →Pixium Vision S.A. (PXMVF) Healthcare & Pipeline Overview
Pixium Vision S.A. is a French bioelectronics firm specializing in brain-machine interface technologies, developing the PRIMA System for bionic vision restoration. This advanced solution targets profound vision impairment, particularly from dry atrophic Age-related Macular Degeneration, by electrically stimulating retinal nerve cells to transmit visual information to the brain.
What Is the Investment Thesis for PXMVF?
Pixium Vision S.A. presents a research-stage investment profile centered on its innovative PRIMA System, a bionic vision solution addressing the high unmet medical need in retinal degeneration, particularly dry atrophic Age-related Macular Degeneration. The company's value drivers are intrinsically linked to the successful progression and regulatory approval of its proprietary technology, which aims to restore sight by electrically stimulating retinal nerve cells. Key growth catalysts include positive outcomes from ongoing and future clinical trials for the PRIMA System, successful fundraising rounds to support its extensive research and development activities, and eventual market penetration post-regulatory approvals. Financially, the company currently operates with a market capitalization of $4.62M, reflecting its pre-revenue, development-stage status. It exhibits significant negative profit and gross margins, at -478473.8% and -40274.6% respectively, indicative of substantial R&D investments without corresponding product sales. The beta of 0.97 suggests its stock volatility is largely in line with the broader market. Investors should monitor clinical trial results, regulatory milestones, and capital structure developments closely, acknowledging the inherent risks associated with early-stage medical device companies, particularly its OTC Other listing status.
Based on FMP financials and quantitative analysis
PXMVF Key Highlights
- Market Capitalization of $4.62M, indicating a micro-cap or pre-commercialization stage, reflecting its focus on research and development.
- Profit Margin of -478473.8%, underscoring significant operational losses typical of a development-stage biotechnology company with high R&D expenditures and no product revenue.
- Gross Margin of -40274.6%, consistent with its pre-revenue status where development costs are expensed without corresponding sales to offset them.
- Beta of 0.97, suggesting that the company's stock price volatility generally tracks the overall market, despite its early development stage.
- Primary focus on the PRIMA System, an advanced bionic vision solution designed to restore sight for individuals with profound vision impairment due to retinal degeneration, addressing a significant unmet medical need.
Who Are PXMVF's Competitors?
PXMVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXMVF's Key Strengths?
- Innovative PRIMA System addresses a high unmet medical need in profound vision impairment due to retinal degeneration.
- Strong foundation in bioelectronics and brain-machine interface technologies.
- Extensive collaborations with leading global research and medical institutions.
- Proprietary technology with potential for significant impact on patient quality of life.
What Are PXMVF's Weaknesses?
- Significant negative profit and gross margins, indicating a pre-revenue, development-stage company.
- Small market capitalization, potentially limiting access to capital and increasing volatility.
- OTC Other listing, which can imply reduced liquidity and disclosure compared to major exchanges.
- High research and development costs inherent in medical device innovation.
What Could Drive PXMVF Stock Higher?
- Announcement of significant positive clinical trial results for the PRIMA System, demonstrating efficacy and safety in target patient populations.
- Achievement of key regulatory milestones, such as successful completion of a clinical phase or submission/approval of regulatory applications (e.g., CE Mark, FDA).
- Successful completion of future capital raising initiatives or strategic funding agreements to support ongoing research and development and commercialization efforts.
- Continued progress in the development and refinement of the PRIMA System technology, enhancing its capabilities and potential applications.
- Expansion and strengthening of strategic collaborations with leading research institutions and medical centers, potentially leading to broader clinical adoption or R&D synergies.
What Are the Key Risks for PXMVF?
- Financial-distress signal — its Altman Z-Score of -8.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -478473.8% and gross margin of -40274.6%, indicating substantial cash burn and reliance on external funding.
- High research and development expenses inherent in the medical device sector, particularly for novel bioelectronic implants, which may continue to impact profitability.
- OTC Other listing status, which presents risks related to limited liquidity, reduced disclosure, and potential price volatility for investors.
- Failure or significant delays in the clinical trials for the PRIMA System, which could jeopardize regulatory approval and commercial viability.
- Challenges in securing sufficient future funding to sustain operations, complete clinical development, and prepare for market launch.
- Intense competition from other companies developing vision restoration therapies, including gene therapies, stem cell treatments, and alternative bionic devices.
What Are the Growth Opportunities for PXMVF?
- **Advancement of PRIMA System through Clinical Trials:** The successful progression of the PRIMA System through its clinical trial phases represents a primary growth driver. Positive clinical data demonstrating efficacy and safety for patients with dry atrophic AMD or other retinal degenerations would significantly de-risk the technology and pave the way for regulatory approvals. The global market for AMD treatments is substantial, with projections indicating billions of dollars annually, providing a significant addressable market upon successful commercialization. Achieving key clinical milestones within the next 3-5 years would be critical for unlocking this potential, attracting further investment, and validating the company's core technology.
- **Expansion into New Indications:** While initially focused on dry atrophic AMD, the underlying technology of the PRIMA System could potentially be adapted or expanded to address other forms of retinal degeneration or conditions leading to profound vision loss. Exploring and initiating clinical programs for additional indications, such as retinitis pigmentosa or other inherited retinal diseases, would broaden the company's potential patient base and market reach. This strategic expansion, likely a 5-10 year endeavor, could diversify revenue streams and enhance the long-term value proposition by leveraging existing technological infrastructure and scientific expertise.
- **Strategic Partnerships and Collaborations:** Pixium Vision S.A. already benefits from collaborations with institutions like Stanford University and Moorfields Eye Hospital. Expanding these relationships or forging new strategic partnerships with larger pharmaceutical or medical device companies could accelerate development, provide access to greater financial resources, enhance manufacturing capabilities, and facilitate broader market access. Such alliances could be instrumental in navigating complex regulatory pathways and commercializing the PRIMA System globally, potentially within a 3-7 year timeframe, by sharing risks and leveraging established infrastructure.
- **Securing Additional Funding and Capital:** As a development-stage company with negative profit and gross margins, securing additional funding is paramount for Pixium Vision S.A.'s continued growth. Successful capital raises, whether through equity financing, grants, or strategic investments, would provide the necessary resources to fund ongoing R&D, conduct larger clinical trials, and prepare for commercial launch. Demonstrating progress in clinical development will be key to attracting investors. The ability to consistently secure adequate funding over the next 2-5 years will directly impact the pace of product development and market entry.
- **Geographic Market Expansion:** Initial regulatory approvals and commercialization efforts are likely to focus on key markets such as Europe and potentially the United States. Successfully navigating the regulatory landscapes of these major markets, including obtaining CE Mark in Europe and FDA approval in the US, would open significant commercial opportunities. Subsequent expansion into other regions with high prevalence of retinal degeneration, such as Asia, would further extend the company's global footprint. This phased geographic expansion, anticipated over a 5-10 year horizon, would be critical for maximizing the commercial potential of the PRIMA System.
What Opportunities Does PXMVF Have?
- Successful clinical trial results and subsequent regulatory approvals for the PRIMA System.
- Expansion of the PRIMA System's indications to other forms of retinal degeneration or blindness.
- Securing additional strategic partnerships or funding to accelerate development and commercialization.
- Geographic market expansion into major healthcare markets like the US and other European countries.
- Advancements in related fields of neuroscience and bioengineering that could enhance the technology.
What Threats Does PXMVF Face?
- Potential for delays or failures in clinical trials, impacting product viability and market entry.
- Challenges in securing sufficient future funding to sustain R&D and commercialization efforts.
- Intense competition from alternative vision restoration therapies, including gene therapies and stem cell treatments.
- Stringent and evolving regulatory approval processes for novel medical devices.
- Market adoption challenges and reimbursement hurdles post-commercialization.
What Are PXMVF's Competitive Advantages?
- Proprietary PRIMA System technology, an advanced sub-retinal implant developed through extensive R&D.
- Specialized expertise in bioelectronics, brain-machine interfaces, and neuromodulation for vision restoration.
- Established network of collaborations with prestigious academic and medical institutions, fostering innovation and clinical validation.
- Significant intellectual property surrounding its bionic vision solution, creating barriers to entry for competitors.
- High regulatory hurdles and capital intensity required for developing and commercializing implantable medical devices, limiting new entrants.
What Does PXMVF Do?
Pixium Vision S.A., established in Paris, France, in 2011, is a pioneering firm at the forefront of bioelectronics and brain-machine interface technologies, with a specialized focus on neuromodulation. The company's core mission revolves around addressing profound vision impairment through innovative solutions. Its flagship product, the PRIMA System, represents an advanced bionic vision solution meticulously engineered to restore sight for individuals suffering from severe vision loss. This often includes patients diagnosed with retinal degeneration, prominently the dry atrophic form of Age-related Macular Degeneration (AMD), as well as other debilitating conditions that lead to blindness. The operational principle of the PRIMA System is rooted in its ability to circumvent damaged natural photoreceptor cells within the retina. Instead, it employs a sophisticated mechanism to electrically stimulate the inner retina's nerve cells. These stimulated nerve cells then effectively convey visual data via the optic nerve directly to the brain, thereby bypassing the compromised parts of the visual pathway. Pixium Vision S.A. is deeply committed to advancing its technology and clinical understanding through robust collaboration. The company actively partners with a network of distinguished global institutions, including Stanford University, the Institut de la Vision, Moorfields Eye Hospital, the Institute of Ocular Microsurgery, University Hospital, and UPMC. These collaborations are crucial for research, development, and the eventual clinical validation and adoption of its sub-retinal implants, positioning Pixium Vision S.A. as a key innovator in the field of bionic vision restoration.
What Products and Services Does PXMVF Offer?
- Develops advanced bionic vision systems to restore sight for individuals with profound vision impairment.
- Specializes in bioelectronics and brain-machine interface technologies.
- Focuses on neuromodulation to stimulate nerve cells.
- Primary product is the PRIMA System, a sub-retinal implant.
- Aims to treat retinal degeneration, including dry atrophic Age-related Macular Degeneration (AMD).
- Functions by electrically stimulating the inner retina's nerve cells, bypassing damaged photoreceptors.
- Collaborates with leading academic and medical institutions globally for research and development.
- Engages in extensive research and development to advance its proprietary technology.
How Does PXMVF Make Money?
- Primarily focused on research and development (R&D) of its proprietary medical device, the PRIMA System.
- Seeks to obtain regulatory approvals (e.g., CE Mark, FDA approval) for the PRIMA System to enable commercialization.
- Anticipates future revenue generation from the sale of the PRIMA System to hospitals and specialized clinics upon successful market entry.
- May explore licensing agreements or strategic partnerships for technology development or distribution in the future.
- Currently operates as a pre-revenue company, with significant investment in clinical trials and product development.
What Industry Does PXMVF Operate In?
Pixium Vision S.A. operates within the highly specialized and innovative Medical - Instruments & Supplies industry, a sub-segment of the broader Healthcare sector. The company's niche is bioelectronics and brain-machine interface technologies, specifically targeting vision restoration for conditions like Age-related Macular Degeneration (AMD). This market is characterized by a high unmet medical need, particularly for advanced forms of retinal degeneration where current treatments are limited. The competitive landscape includes other companies developing retinal implants, gene therapies, and stem cell-based treatments for vision loss, though Pixium Vision's sub-retinal implant approach offers a distinct pathway. The industry is driven by technological advancements, significant R&D investment, and stringent regulatory processes. Pixium Vision's positioning as a developer of a bionic vision system places it in a high-growth potential segment, contingent on clinical success and market adoption.
Who Are PXMVF's Key Customers?
- Individuals experiencing profound vision impairment due to retinal degeneration.
- Patients specifically diagnosed with the dry atrophic form of Age-related Macular Degeneration (AMD).
- Ophthalmologists and retina specialists who treat patients with severe vision loss.
- Hospitals, specialized eye clinics, and surgical centers that perform advanced ocular procedures.
- Research institutions and clinical trial sites involved in vision restoration studies.
F-Score 3/9Financial Health
Pixium Vision S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.57 places it in the distress zone, a signal of elevated financial risk.
PXMVF Valuation & Market Position
With a $4.62M market cap, Pixium Vision S.A. sits in the micro-cap segment of the market. Relative to its peer group, PXMVF's quantitative score of 43/100 is below the peer average of 67/100.
Key Financial Metrics
Return on assets is -77.3%, showing how much profit it generates from its asset base. A current ratio of 1.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Pixium Vision S.A. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Lloyd Diamond. PXMVF has traded publicly since 2021.
PXMVF Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with inside knowledge see potential upside, signaling confidence despite current market conditions.
- The community sentiment shows growing optimism about Pixium's clinical trials, indicating belief in their technology's progress.
- There's increasing chatter about potential partnerships, which could validate their technology and provide much-needed funding, similar to early biotech deals.
- The market perception seems to be shifting from skepticism to cautious optimism as more data emerges, hinting at a potential turnaround.
Bear Case
- Lack of concrete revenue streams raises concerns about long-term sustainability, a common worry for pre-revenue biotech companies.
- Community sentiment reflects anxieties about regulatory hurdles, a significant risk for medical device companies seeking market approval.
- Past delays in product launches have created a sense of unease, making investors wary of future timelines, like the issues faced by other innovative medical firms.
- The overall market perception is still cautious due to the high cash burn rate, prompting questions about their ability to stay afloat without further funding, reminiscent of other struggling biotechs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PXMVF Latest News
No recent news available for PXMVF.
PXMVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PXMVF.
Price Targets
Wall Street price target analysis for PXMVF.
PXMVF MoonshotScore
What does this score mean?
The MoonshotScore rates PXMVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lloyd Diamond
Chief Executive Officer
The specific career history, educational background, and previous roles for Lloyd Diamond are not provided in the source data. Therefore, a detailed biographical sketch cannot be furnished at this time.
Track Record: Key achievements, strategic decisions, and company milestones under Lloyd Diamond's leadership are not detailed in the provided source materials. Consequently, a specific track record cannot be outlined.
PXMVF OTC Market Information
Pixium Vision S.A. trades on the OTC Other tier, which is the lowest of the three primary tiers for OTC Markets (OTC Pink, OTCQB, OTCQX, and OTC Other). Companies on the OTC Other tier typically have limited or no public disclosure, and may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQB or OTCQX, let alone major exchanges like NYSE or NASDAQ. This tier is often associated with companies that are not required to report to the SEC, or those that have failed to meet the standards of other tiers. Investors should be aware that this classification generally indicates higher risk and less transparency compared to companies listed on regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Liquidity:** The OTC Other tier often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- **Reduced Disclosure:** Companies on this tier may have minimal or no public financial reporting, leading to a lack of transparency for investors.
- **Price Volatility:** Low liquidity and limited information can contribute to extreme price fluctuations, increasing investment risk.
- **Regulatory Scrutiny:** OTC Other stocks may be subject to less regulatory oversight compared to major exchanges, potentially exposing investors to greater risks.
- **Capital Raising Challenges:** The lack of transparency and liquidity can make it more challenging for the company to raise capital from institutional investors.
- Verify the company's latest financial statements and operational reports, if available, directly from the company or regulatory filings.
- Thoroughly review all available information regarding the PRIMA System's clinical trial status, results, and regulatory pathway.
- Assess the experience and track record of the management team, seeking information beyond what is publicly disclosed on OTC platforms.
- Investigate the company's capital structure, outstanding shares, and any recent financing activities.
- Evaluate the competitive landscape and the unique advantages or disadvantages of Pixium Vision's technology.
- Understand the specific regulatory requirements and timelines for medical device approval in target markets.
- Research any news or announcements from the company regarding its collaborations and partnerships.
- Active development of a specific, innovative product (PRIMA System) addressing a clear medical need.
- Established in 2011, indicating a sustained effort in research and development over more than a decade.
- Headquartered in Paris, France, suggesting a formal corporate structure in a regulated environment.
- Active collaborations with distinguished academic and medical institutions like Stanford University and Moorfields Eye Hospital.
- Presence of a named CEO, Lloyd Diamond, overseeing company operations and a team of 40 employees.
Pixium Vision S.A. Healthcare Stock: Key Questions Answered
What is the PRIMA System and how does it work?
The PRIMA System is Pixium Vision S.A.'s flagship bionic vision solution, designed to restore sight for individuals with profound vision impairment, particularly those suffering from retinal degeneration like dry atrophic Age-related Macular Degeneration (AMD). This advanced sub-retinal implant functions by bypassing the damaged natural photoreceptor cells in the retina. Instead, it electrically stimulates the inner retina's nerve cells, which are still functional. These stimulated nerve cells then transmit visual data via the optic nerve directly to the brain, effectively creating a form of artificial vision. The system aims to provide a functional visual perception, improving the quality of life for patients for whom other treatments are not effective.
How does Pixium Vision S.A. navigate regulatory approval processes for its medical devices?
Pixium Vision S.A., operating in the highly regulated medical device sector, must navigate stringent regulatory approval processes to bring its PRIMA System to market. While specific details of its regulatory track record are not provided, the company's focus on clinical trials indicates a pathway towards demonstrating safety and efficacy to regulatory bodies such as the European Medicines Agency (EMA) for CE Mark approval in Europe, and the U.S. Food and Drug Administration (FDA) for market authorization in the United States. Compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards is essential throughout development. The company's collaborations with leading medical institutions likely aid in adhering to these rigorous standards and generating the necessary clinical evidence for regulatory submissions.
What are the primary financial challenges facing Pixium Vision S.A. as a development-stage company?
As a development-stage company focused on innovative medical devices, Pixium Vision S.A. faces several significant financial challenges. The company currently reports a market capitalization of $4.62M, coupled with substantial negative profit and gross margins of -478473.8% and -40274.6% respectively. These figures indicate that the company is pre-revenue and incurring significant expenses, primarily from its extensive research and development activities and clinical trials for the PRIMA System. A key challenge is securing consistent and sufficient funding to cover these ongoing operational costs, advance its clinical pipeline, and prepare for eventual commercialization. The ability to manage cash burn effectively and attract further investment will be critical for its long-term financial viability and progression towards profitability.
What is Pixium Vision S.A.'s strategy for commercializing the PRIMA System?
Pixium Vision S.A.'s commercialization strategy for the PRIMA System is currently in its developmental phase, contingent upon successful clinical trial outcomes and regulatory approvals. The company's focus is on establishing the safety and efficacy of its bionic vision solution through rigorous clinical studies, which are foundational for market entry. Upon achieving regulatory clearances, such as CE Mark in Europe or FDA approval in the U.S., the strategy would likely involve targeting specialized ophthalmology centers and retina specialists who treat patients with profound vision impairment. Leveraging its existing collaborations with prominent medical institutions could facilitate early adoption and build clinical advocacy. The company would also need to address market access and reimbursement strategies to ensure the PRIMA System is accessible to eligible patients.
What are the key factors to evaluate for PXMVF?
Pixium Vision S.A. (PXMVF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does PXMVF data refresh on this page?
PXMVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PXMVF's recent stock price performance?
Pixium Vision S.A. (PXMVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative PRIMA System addresses a high unmet medical need in profound vision impairment due to retinal degeneration. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PXMVF overvalued or undervalued right now?
Valuing Pixium Vision S.A. (PXMVF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information based solely on provided source data.
- CEO background and track record details were not provided in the source data.
- Competitor 'BerGenBio ASA' is listed as a peer but operates in a different therapeutic area (oncology vs. bionic vision), as per the provided FMP PEER TICKERS.